HYUNDAI PHARMACEUTICAL CO., LTD
004310 | KO
Overview
Corporate Details
- ISIN(s):
- KR7004310009
- LEI:
- Country:
- South Korea
- Address:
- 충청남도 천안시 동남구 풍세면 잔다리길 55, 천안시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 9.0 KB | ||
| 2025-07-14 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 14.8 KB | ||
| 2025-07-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.05)
|
Korean | 876.8 KB | ||
| 2025-04-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 10.4 KB | ||
| 2025-04-28 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 8.5 KB | ||
| 2025-04-14 00:00 |
Quarterly Report
분기보고서 (2025.02)
|
Korean | 827.4 KB | ||
| 2025-02-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 23.9 KB | ||
| 2025-02-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.8 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 11.9 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
[첨부추가]사업보고서 (2024.11)
|
Korean | 524.8 KB | ||
| 2025-02-12 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 15.8 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.9 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 109.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 8.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 6.1 KB |
Automate Your Workflow. Get a real-time feed of all HYUNDAI PHARMACEUTICAL CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for HYUNDAI PHARMACEUTICAL CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HYUNDAI PHARMACEUTICAL CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
United States of America
ACXP
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
United States of America
ADAP
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
South Korea
179530
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
United States of America
ADCT
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
Switzerland
ADXN
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
United States of America
ADIL
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
United States of America
ACET
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
United States of America
ANL
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
United States of America
ADMA
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
United States of America
ADVM